New hope for Tough-to-Treat skin cancer: experimental combo targets immune system
NCT ID NCT06784648
Summary
This early-stage trial is testing a new three-drug combination for people with advanced melanoma that has spread or cannot be removed by surgery and has worsened after standard immunotherapy. The study aims to find a safe and effective dose of the experimental drug BI-1607 when given with two existing immunotherapies (ipilimumab and pembrolizumab), hoping this trio will better help the body's immune system fight the cancer. It will involve about 35 participants to check safety, how the drugs work in the body, and if tumors shrink.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Universitatsmedizin Berlin
Berlin, Germany
-
Hospital Universitario Vall d'Hebron
Barcelona, Spain
-
Sarah Cannon Research Institute UK
London, Greater London, W1G 6AD, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
University Hospital 12 de Octubre
Madrid, Spain
-
University Hospital Essen
Essen, Germany
-
University Hospital Heidelberg
Heidelberg, Germany
-
University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg and Clinical Cooperation Unit Dermato-Oncology(G300) German Cancer Research Center(DKFZ)
Mannheim, Germany
-
Velindre Cancer Centre
Cardiff, Wales, CF14 2TL, United Kingdom
Conditions
Explore the condition pages connected to this study.